|  |
| --- |
| **Supplemental Table 1.** Overall Change From Baseline for Additional Efficacy Assessments  |
| **Assessment** | **nVNS** | **SoC**  | **Treatmentdifference** | ***p* value** |
| **n** | **Obs** | **LSM change from BL (95% CI)** | **n** | **Obs** | **LSM change from BL (95% CI)** | **LSM (95% CI)** |
| FiO2 | 47 | 168 | 0.04(–0.01 to 0.09) | 50 | 224 | 0.03(–0.02 to 0.07) | 0.01(–0.05 to 0.08) | 0.650 |
| Oxygen saturation, % | 47 | 168 | 0.41(0.06-0.75) | 50 | 224 | 0.28(–0.02 to 0.57) | 0.13(–0.32 to 0.59) | 0.568 |
| Lymphocytes, no./µL | 27 | 39 | 689.56(459.09-920.03) | 35 | 52 | 472.19(273.05-671.33) | 217.37 (–93.30 to 528.05) | 0.166 |
| Platelets, no./µL | 27 | 39 | 83191.27(53475.70-112906.80) | 35 | 52 | 66150.90 (40576.65-91725.16) | 17040.37(–22152.80 to 56233.57) | 0.387 |
| TNF‑α, pg/mL | 23 | 29 | –1.66(–6.36 to 3.04) | 28 | 39 | –2.26(–6.06 to 1.55) | 0.60(–5.48 to 6.67) | 0.849 |
| IL-6, pg/mL | 24 | 32 | 25.07(–80.60 to 130.73) | 31 | 44 | 57.70(–34.35 to 149.75) | –32.64(–172.81 to 107.53) | 0.642 |
| Ferritin, ng/mL | 24 | 30 | –343.68(–485.18 to –202.17) | 30 | 41 | –214.93(–339.39 to –90.48) | –128.74(–317.20 to 59.71) | 0.176 |
| Haptoglobin, mg/dL | 22 | 28 | –104.31(–141.69 to –66.92) | 29 | 40 | –66.63(–99.05 to –34.22) | –37.67(–87.54 to 12.20) | 0.135 |
|  | **n** | **Mean (SD)** | **n** | **Mean (SD)** |  |  |
| Length of hospital stay, mean (SD), d | 47 | 11.0 (8.0) | 49 | 10.1 (6.7) | NA | 0.840a |
| Length of ICU stay, mean (SD), d | 8 | 8.0 (6.1) | 2 | 7.0 (1.4) | NA | 0.933a |
| *p* values are from *F* tests comparing the change from baseline overall (ie, for all postbaseline observations) for the nVNS and SoC groups unless otherwise indicated.aFrom Wilcoxon rank sum test.Abbreviations: BL, baseline; FiO2, fraction of inspired oxygen; IL, interleukin; LSM, least squares mean; NA, not applicable; nVNS, non-invasive vagus nerve stimulation; obs, observations; SoC, standard of care; TNF, tumor necrosis factor. |
|  |